Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior vice president of business development.
He brings over 25 years of life science experience to his new role at the German firm, with expertise in the areas of strategic planning, corporate and business development, alliance and project management, new product planning, marketing and sales.
Jonas Renz, managing director of Sterna, said: “Christian is a proven senior executive with extensive leadership experience and an impressive track record.
“He was instrumental in a number of successful business transformations and high-value transactions across various therapeutic areas that are highly relevant to Sterna.”
Prior to his time with the Vectura Group, Pangratz served as a non-executive director on SkyePharma’s board and before this he was executive vice president of business development at the company.
He has also held roles for Nektar Therapeutics, Bayer and Pfizer.
Commenting on his new move, Pangratz said: “I am delighted to be joining Sterna at such an exciting time.
“Within the past ten years, the company has grown into an accomplished immunology player with four promising phase II programmes and is now poised for its next strategic move.”